Slideshow

SGLT2 Inhibitors: 5 True or False Questions

Click through these 5 statements about the "gliflozin" class of diabetes drugs for a test of your recall and retention.

The sodium glucose cotransporter-2 inhibitor class of antihyperglycemic agents are proven both safe and effective in treating type 2 diabetes. What do you know about details of registration trials and post-marketing research on the "gliflozins?"Use this first installment of 5 True/False statements above to test your recall and retention.Links for additional information provided below and in slide captions.  References1. FDA approves SGLT2 inhibitor STEGLATRO™ (ertugliflozin) and fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) for adults with type 2 diabetes [press release]. New York: Pfizer Inc; December 22, 2017.  Accessed January 22 2018. :2. Pinto LC, Rados DV, Remonti LR, et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7: A58. Published online November 11, 2015. doi:  10.1186/1758-5996-7-S1-A58.3. Zinman B, Wanner C ,Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.4. Zhang XL, Zhu QQ, Yu-Han C, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with trial sequential analysis.  J Am Heart Assoc. 2018;7:e007165. DOI: 10.1161/JAHA.117.0071655. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) [FDA Drug Safety Communication]. May 16 2017.  Accessed January 22, 2018.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
© 2024 MJH Life Sciences

All rights reserved.